VB 15010
Alternative Names: VB-15010Latest Information Update: 09 Jul 2024
At a glance
- Originator Shenzhen Yangli Pharmaceutical Technology
- Class Antineoplastics
- Mechanism of Action Poly(ADP-ribose) polymerase-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 05 Apr 2024 Preclinical trials in Cancer in China (Parenteral) prior to April 2024
- 05 Apr 2024 Pharmacokinetics and pharmacodynamics data from the preclinical studies in Cancer presented at 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 31 Mar 2024 Shenzhen Yangli Pharmaceutical Technology anticipates IND filing in the first quarter of 2024